This product, although approved, is not yet available to purchase via TheSocialMedwork. However, if you are interested in staying informed please leave your email address, and we will update you as soon as we’ll be able to source it and offer it for purchase.
|Manufacturer||Eli Lilly and Co.|
|Indication||HR-positive HER2-negative advanced or metastatic breast cancer|
|Mode of Action||Kinase inhibitor (targeted therapy)|
|Approval Status||FDA approved (USA)|
If you are interested in other medicines for breast cancer, please visit our breast cancer page.
Verzenio (abemaciclib) is a kinase inhibitor approved by the FDA on September 28, 2017 for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer 
In combination with an endocrine therapy, called fulvestrant, in patients with disease progression following endocrine therapy 
As monotherapy in patients with with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting 
Abemaciclib is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6 which works by inhibiting the growth of cancer cells. There are two other drugs in this class that are approved for certain patients with breast cancer, palbociclib approved in February 2015 and ribociclib approved in March 2017 . Unlike these two other drugs, Verzenio (abemaciclib) can be given as a monotherapy to patients who were previously treated with endocrine therapy and chemotherapy .
Verzenio (abemaciclib) was approved by the FDA on September 28, 2017 . We have already contacted our sourcing partners and we will offer this product on our website as soon as we’ll be able to source it for our patients.
— Charles, USA
— Tomasz, Poland
— Regina, US
— Stephen, UK
— Dee, Australia
— Charlotte, The Netherlands
— Haoyu, China
— Frank, Virginia, USA
— Pa Tric, Germany
— Milos, Serbia & Montenegro